(Q33713590)

28 July 2017

1 reference

title

Pneumococcal vaccines: history, current status, and future directions (English)

1 reference

28 July 2017

1 reference

Butler JC

1

1 reference

28 July 2017

Shapiro ED

series ordinal

2

1 reference

28 July 2017

Carlone GM

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

American Journal of Medicine

28 July 2017

1 reference

28 July 2017

107

1 reference

28 July 2017

69S-76S

1 reference

28 July 2017

1A

1 reference

Bacterial meningitis in the United States in 1995. Active Surveillance Team

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

A Reassessment of Pneumococcal Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal antibody levels one decade after immunization of healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Persistence of Pneumococcal antibodies in human subjects following vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Response of Patients with Hodgkin's Disease to Pneumococcal Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Antibody Response to Pneumococcal Vaccine in Patients with Multiple Myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Anti-pneumococcal antibody response in normal subjects: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Inefficacy of pneumococcal vaccine in a high-risk population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal bacteremia in Monroe County, New York

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Safety of revaccination with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Cytokines as potential vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Antibody response to pneumococcal vaccination in children younger than five years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal disease: prospects for a new generation of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

DNA vaccines for emerging infectious diseases: what if?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

Six newly recognized types of Streptococcus pneumoniae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900105-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00105-9

1 reference

release_47l3lm5mdbd7dnucpo4bbmxw2m

28 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/47l3lm5mdbd7dnucpo4bbmxw2m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference